1.29BMarket Cap-7598P/E (TTM)
35.620High32.570Low724.84KVolume32.970Open32.270Pre Close24.89MTurnover2.51%Turnover RatioLossP/E (Static)38.04MShares42.50052wk High5.11P/B977.16MFloat Cap12.57052wk Low--Dividend TTM28.83MShs Float63.690Historical High--Div YieldTTM9.45%Amplitude10.800Historical Low34.336Avg Price1Lot Size
Tarsus Pharmaceuticals Stock Forum
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1.
Year-to-date sales totaled $65.5 million.
The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%.
Tarsus expanded payer coverage, incl...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
How to identify Marubozu Candle
Weekly & and daily Marubozu candle occured for TARSUS...
drop in price despite FDa approval
ALERT ON: $23.02
ON THE WATCH: $23.18
🥇 SIGNED OF MORE UPTREND: $23.28
NEED IT TO BREAK OVER: $23.36
key indicator for MORE uptrend $23.44
confirmation uptrend - $23.54
OK I SEE YOU - $23.71
mini breakout - $23.87
Prepare for a bigger breakout: $23.97. $Tarsus Pharmaceuticals (TARS.US)$
No comment yet